WO2001010435A1 - Patch - Google Patents
Patch Download PDFInfo
- Publication number
- WO2001010435A1 WO2001010435A1 PCT/JP2000/005269 JP0005269W WO0110435A1 WO 2001010435 A1 WO2001010435 A1 WO 2001010435A1 JP 0005269 W JP0005269 W JP 0005269W WO 0110435 A1 WO0110435 A1 WO 0110435A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- parts
- patch
- penilylamide
- acid
- Prior art date
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims abstract description 12
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims description 25
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 21
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 235000002566 Capsicum Nutrition 0.000 claims description 5
- 239000006002 Pepper Substances 0.000 claims description 5
- 235000016761 Piper aduncum Nutrition 0.000 claims description 5
- 235000017804 Piper guineense Nutrition 0.000 claims description 5
- 235000008184 Piper nigrum Nutrition 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- 244000203593 Piper nigrum Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- -1 nonyluric acid Chemical compound 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 206010040880 Skin irritation Diseases 0.000 description 9
- 230000036556 skin irritation Effects 0.000 description 9
- 231100000475 skin irritation Toxicity 0.000 description 9
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000004745 nonwoven fabric Substances 0.000 description 6
- 229940116257 pepper extract Drugs 0.000 description 6
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 6
- 239000004584 polyacrylic acid Substances 0.000 description 6
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 6
- 239000005995 Aluminium silicate Substances 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 235000012211 aluminium silicate Nutrition 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000011505 plaster Substances 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 229960002920 sorbitol Drugs 0.000 description 5
- 241000722363 Piper Species 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 229940007061 capsicum extract Drugs 0.000 description 3
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940037001 sodium edetate Drugs 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AKDLSISGGARWFP-UHFFFAOYSA-N Homodihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCCC(C)C)=CC=C1O AKDLSISGGARWFP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- VQEONGKQWIFHMN-UHFFFAOYSA-N Nordihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCC(C)C)=CC=C1O VQEONGKQWIFHMN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940024545 aluminum hydroxide Drugs 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001545 hydrotalcite Drugs 0.000 description 2
- 229910001701 hydrotalcite Inorganic materials 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- APLNAFMUEHKRLM-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)N=CN2 APLNAFMUEHKRLM-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical compound O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- XJQPQKLURWNAAH-UHFFFAOYSA-N dihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCC(C)C)=CC=C1O XJQPQKLURWNAAH-UHFFFAOYSA-N 0.000 description 1
- RBCYRZPENADQGZ-UHFFFAOYSA-N dihydrocapsaicin Natural products COC1=CC(COC(=O)CCCCCCC(C)C)=CC=C1O RBCYRZPENADQGZ-UHFFFAOYSA-N 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- GOBFKCLUUUDTQE-UHFFFAOYSA-N homodihydrocapsaicin-II Natural products CCC(C)CCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 GOBFKCLUUUDTQE-UHFFFAOYSA-N 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A patch comprising a water-soluble polymer as the base, characterized by containing a capsaicinoid and N-vanillylnonanamide in amounts per 100 g of the base of 0.0002 to 0.005 g and 0.0005 to 0.007 g respectively.
Description
明細書 Specification
貼付剤 技術分野 Patch Technical Field
本発明は、 低刺激性温感貼付剤に関する。 従来技術 The present invention relates to a hypoallergenic warming patch. Conventional technology
貼付剤は、 配合する薬物を持続的に経皮投与できる点で非常に優れた投与形態 である。 しかしながら、 貼付剤にもいくつかの問題点がある。 その問題のうち最 も件数が多いのが貼付剤を貼った患者の貼付部位に発生する皮膚刺激である。 特にトウガラシエキス、 ノニル酸ヮニリルアミド等に代表される温感成分を配 合した場合、 さらに皮膚に刺激を与え、 かぶれ等を生じさせるおそれがあるため、 その配合量は可能な限り低く抑えることが望ましい。 Patches are an excellent dosage form in that the drug to be incorporated can be continuously transdermally administered. However, patches also have some problems. The most frequent of these problems is skin irritation occurring at the site where the patch was applied to patients. In particular, when a warming ingredient represented by pepper extract, nonyl acid phenylylamide, etc. is combined, it may further irritate the skin and cause rashes. .
本発明の目的は、 温感効果に優れ、 かつ、 皮膚刺激の少ない貼付剤を提供する ことである。 発明の開示 An object of the present invention is to provide a patch having an excellent warming effect and less skin irritation. Disclosure of the invention
本発明者は、 上記目的に鑑み鋭意研究を重ねた結果、 カブサイシノイド及びノ 二ル酸ヮ二リルアミドを併用して配合した場合、 皮膚刺激の少ない低用量であつ ても十分な温感刺激が得られることを見出し、 本発明を完成するに至つた。 The present inventor has conducted intensive studies in view of the above-mentioned object, and as a result, when combined with cabsaicinoid and nonyluric acid perilylamide, a sufficient warm stimulus was obtained even at a low dose with little skin irritation. And found that the present invention was completed.
即ち、 本発明は、 水溶性高分子基剤を含有する貼付剤において、 カブサイシノ イド及びノニル酸ヮニリルアミドを配合し、 かつ、 基剤 1 0 0 gに対するカプサ イシノイドの配合量を [X] ( g ) 、 ノニル酸ヮニリルアミドの配合量を [Y] ( g ) とした場合、 [X]が 0 . 0 0 0 2〜0 . 0 0 5であり、 [Y] が 0 . 0 0 0 5〜 0 . 0 0 7であることを特徴とする貼付剤である。 That is, the present invention relates to a patch containing a water-soluble polymer base, in which cabsaicinoid and nonyl acid penilylamide are blended, and the amount of capsaicinoid in 100 g of the base is [X] (g). Assuming that the blending amount of nonyl acid penilylamide is [Y] (g), [X] is 0.002 to 0.05 and [Y] is 0.0005 to 0.05. A patch characterized in that the patch is 07.
また、 本発明は、 水溶性高分子基剤を含有する貼付剤において、 カブサイシノ イド及びノニル酸ヮニリルアミドを配合し、 かつ、 基剤 1 0 0 gに対するカプサ イシノイドの配合量を [X] ( g ) 、 ノニル酸ヮニリルアミドの配合量を [Y] ( g ) とした場合、 [Y]が 0 . 0 0 0 5〜0 . 0 0 3であり、 かつ、 [X] + 0 . 6 X [Y] が 0 . 0 0 2 0〜0 . 0 0 2 8であることを特徴とする貼付剤である。 Further, the present invention provides a patch containing a water-soluble polymer base, in which cabsaicinoid and nonyl acid penilylamide are blended, and the amount of the capsaicinoid in 100 g of the base is [X] (g). Assuming that the blending amount of nonyl acid penilylamide is [Y] (g), [Y] is 0.005 to 0.003, and [X] +0.6 X [Y] Is 0.0000 to 0.0208.
また、 本発明は、 水溶性高分子基剤を含有する貼付剤において、 カブサイシノ イド及びノニル酸ヮニリルアミドを配合し、 かつ、 基剤 1 0 0 gに対するカプサ イシノイドの配合量を [X] ( g ) 、 ノニル酸ヮニリルアミドの配合量を [Y] ( g )
とした場合、 [Y]が 0. 0005〜0. 007であり、 かつ、 [Χ] + 0. 6 X [Υ] が 0. 0046〜 0. 0052であることを特徴とする貼付剤である。 発明実施の形態 In addition, the present invention provides a patch containing a water-soluble polymer base, in which cabsaicinoid and nonyl acid penilylamide are compounded, and the amount of capsaicinoid in 100 g of the base is [X] (g). , The amount of nonyl acid penilylamide is [Y] (g) Wherein [Y] is 0.0005 to 0.007, and [Χ] + 0.6 X [Υ] is 0.0046 to 0.0052. . Embodiment of the Invention
本発明は、 水溶性高分子基剤にカブサイシノィド及びノニル酸ヮニリルアミド を配合すること、 及びその配合量を低用量に設定している点を特徴とする。 The present invention is characterized in that cabsaicinide and nonyl acid penilylamide are blended in a water-soluble polymer base, and that the blending amount is set to a low dose.
(温感成分) (Warmth ingredient)
本発明においてカブサイシノィドとは、 カブサイシン及びその同族体を意味し、 具体的には、 例えばカブサイシン、 ジヒドロカブサイシン、 ノルジヒドロカプサ イシン、 ホモジヒドロカプサイシンなどを挙げることができる。 In the present invention, capsaicinoid means capsaicin and homologues thereof, and specific examples include capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin and the like.
また、 カブサイシノイドは、 トウガラシ由来のものが好ましく、 トウガラシェ キス、 トウガラシ末、 トウガラシチンキなどを使用することができる。 In addition, the turnip cycinoid is preferably derived from a pepper, and may include pepper shakes, pepper powder, and pepper tincture.
基剤 100 gに対するカブサイシノイドの配合量を [X] (g) とした場合、 温 感効果の点から [X]は 0. 0002以上が好ましく、 皮膚刺激低減の点からは 0. 005以下が好ましい。 When the compounding amount of cabsaicinoid per 100 g of base is [X] (g), [X] is preferably 0.0002 or more from the viewpoint of warming effect and 0.005 or less from the viewpoint of reducing skin irritation. .
基剤 100 gに対するノニル酸ヮニリルアミドの配合量を [Y] (g) とした場 合、 温感効果の点から [Y]は 0. 0005以上であることが好ましく、 皮膚刺激 低減の点からは 0. 007以下であることが好ましい。 さらに、 肩こり治療用貼 付剤においては [Y]は 0. 0005〜0. 003が好ましく、 腰痛治療用貼付剤 においては [Y]は 0. 0005〜0. 007が好ましい。 When the amount of nonyl acid penilylamide per 100 g of base is [Y] (g), [Y] is preferably 0.0005 or more from the viewpoint of warm feeling effect, and from the viewpoint of reducing skin irritation. It is preferably 0.007 or less. Furthermore, [Y] is preferably 0.0005 to 0.003 in the patch for treating stiff shoulder, and [Y] is preferably 0.0005 to 0.007 in the patch for treating back pain.
また、 本発明者は、 ノニル酸ヮニリルアミドの温感付与効果がカブサイシノィ ドの約 0. 6倍であることを見出し、 この知見に基づき試験を行ったところ、 力 プサイシノィドの配合量 [X]とノニル酸ヮニリルアミドの配合量 [Y]の関係は、 肩こり治療用貼付剤においては [Χ] + 0· 6 Χ [Υ] が 0. 0020〜0. 00 28の範囲が好ましく、 腰痛治療用貼付剤においては [Χ] + 0. 6 X [Υ] が 0. 0046〜0. 0052の範囲が好ましいことが確認された。 Further, the present inventor found that the effect of imparting warmth of nonyl acid penilylamide was about 0.6 times that of cabsaicinide, and conducted a test based on this finding. [関係] + 0.6 ヮ [ヮ] is preferably in the range of 0.0002 to 0.0028 in the patch for the treatment of stiff shoulder in the patch for the treatment of low back pain. It was confirmed that [Χ] +0.6 X [Υ] was preferably in the range of 0.0046 to 0.0052.
(水溶性高分子基剤) (Water-soluble polymer base)
本発明において、 水溶性高分子基剤の組成には特に制限はなく、 いずれの組成 のものも使用し得る。 例えばゼラチン、 ポリアクリル酸、 ポリアクリル酸ナトリ ゥムなどのポリアクリル酸塩、 ポリアクリル酸部分中和物、 ポリアクリル酸デン プン、 ポリビニルアルコール、 ポリビニルピロリ ドン、 ポリアクリル酸共重合体、 ヒドロキシプロピルセルロース、 カルメロースナトリウム、 メチルセルロース、
無水マレイン酸共重合体、 N—ビニルァセ夕ミド共重合体、 メタクリル酸共重合 体などを挙げることができる。 水溶性高分子基剤の水含有量は、 貼付したときの 冷却効果の点から基剤全体に対して 3 5〜8 0重量%であることが好ましい。 In the present invention, the composition of the water-soluble polymer base is not particularly limited, and any composition may be used. For example, gelatin, polyacrylic acid, polyacrylic acid salts such as sodium polyacrylate, partially neutralized polyacrylic acid, starch polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, polyacrylic acid copolymer, hydroxypropyl Cellulose, carmellose sodium, methylcellulose, Examples thereof include a maleic anhydride copolymer, an N-vinyl acetate copolymer, and a methacrylic acid copolymer. The water content of the water-soluble polymer base is preferably 35 to 80% by weight based on the whole base in view of the cooling effect when applied.
(その他の成分) (Other ingredients)
本発明は、 必須成分の他に 1一メン! ^一ル、 d l —メントール、 ハツ力油、 力 ンフル、 マレインク口フエ二ラミン、 塩酸ジフェンヒドラミン、 ァズレン、 グァ ィァズレンスルホン酸ナトリウム、 グリチルレチン酸、 グリチルリチン酸及びそ の塩、 酢酸トコフエロール、 d 1—カンフルなどの薬剤を配合することもできる。 また、 上記成分の他に、 通常使用される基剤成分、 例えば賦型剤 (無水珪酸、 カオリン、 シクロデキストリン、 酸化亜鉛、 酸化チタン、 珪酸アルミニウム保湿 剤など) 、 保湿剤 (グリセリン、 ジグリセリン、 トリグリセリン、 プロピレング リコール、 ブチレングリコール、 ポリエチレングリコール、 d _ソルビトールな ど) 、 粘着剤 (力ルポキシビ二ルポリマ一、 ポリビニルアルコールなどの合成高 分子化合物またはアラビアゴム、 キサンタンガンなどの天然高分子化合物など) 、 界面活性剤 (グリセリン脂肪酸エステル、 ポリオキシエチレンヒマシ油、 ポリオ キシエチレン硬化ヒマシ油、 ソルビ夕ン脂肪酸エステル、 ポリソルベート 8 0、 ポリソルベート 6 0、 セスキォレイン酸ソルビタンなど) 、 架橋剤 (酸化亜鉛、 水酸化アルミニウム、 アルミニウムグリシネート、 ジヒドロキシアルミニウムァ ミノアセテート、 合成ヒドロタルサイトなどの多価金属化合物など) などを配合 することができる。 In addition to the essential ingredients, the present invention is also applicable to the following ingredients: menthol, menthol, heart oil, forceful, maleink mouth feniramine, diphenhydramine hydrochloride, azulene, sodium guaizulene sulfonate, glycyrrhetinic acid Drugs such as glycyrrhizic acid and its salts, tocopherol acetate, and d1-camphor can also be added. In addition to the above components, commonly used base components such as excipients (silicic acid anhydride, kaolin, cyclodextrin, zinc oxide, titanium oxide, aluminum silicate moisturizer, etc.), moisturizers (glycerin, diglycerin, Synthetic high molecular compounds such as triglycerin, propylene glycol, butylene glycol, polyethylene glycol, d_sorbitol, etc., adhesives (Ripoxyvinyl polymer, polyvinyl alcohol) or natural high molecular compounds such as gum arabic and xanthan cancer ), Surfactants (glycerin fatty acid ester, polyoxyethylene castor oil, polyoxyethylene hardened castor oil, sorbin fatty acid ester, polysorbate 80, polysorbate 60, sorbitan sesquioleate, etc.) Can be formulated aluminum hydroxide, aluminum glycinate, dihydroxy aluminum § amino acetate, such as polyvalent metal compounds such as synthetic hydrotalcite), and the like.
また、 必要に応じて吸収促進剤、 防腐剤、 抗酸化剤、 着色剤等を配合すること ができる。 Further, if necessary, an absorption promoter, a preservative, an antioxidant, a coloring agent, and the like can be added.
(支持体) (Support)
本発明の貼付剤は通常の貼付剤に使われる支持体、 ライナーなどに展延して通 常の方法により貼付剤とすることができる。 支持体としては柔軟性を有する織布、 不織布、 フィルム、 シートであり、 特に全方向に伸縮性を有する通気性のあるも のが好ましい。 産業上利用可能性 The patch of the present invention can be spread on a support, a liner, or the like used for a conventional patch to form a patch by a usual method. The support is a flexible woven fabric, nonwoven fabric, film, or sheet, and particularly preferably a breathable material having elasticity in all directions. Industrial applicability
本発明により温感効果に優れ、 皮膚刺激の少ない貼付剤の提供が可能となった。 発明を実施するための最良の形態
以下に実施例をあげてさらに詳細に説明する。 ADVANTAGE OF THE INVENTION By this invention, it became possible to provide the patch which is excellent in a warm feeling effect and has little skin irritation. BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in more detail with reference to examples.
実施例 1 (肩こり治療用貼付剤) Example 1 (Patch for stiff shoulder treatment)
ポリエチレングリコール 4. 0重量部、 パラォキシ安息香酸エステル 0. 15 重量部、 1一メントール 0. 25重量部、 インドメタシン 0. 375重量部、 ト ゥガラシエキス (カブサイシノィド濃度はトウガラシエキス全体の 20重量%) 0. 01重量部、 ノニル酸ヮニリルアミド 0. 001重量部、 濃グリセリン 23 重量部、 メタケイ酸アルミン酸金属塩 0. 08重量部を均一に分散し 1液とした < ゼラチン 1. 0重量部、 ポリビニルアルコール 3. 20重量部、 カルメロースナ トリウム 3. 00重量部、 ポリアクリル酸ナトリウム 5. 0重量部、 ヒドロキシ プロピルセルロース 0. 3重量部、 70 %D—ソルビトール 14重量部、 力オリ ン 3. 0重量部、 酒石酸 1. 2重量部、 ェデト酸ナトリウム 0. 1重量部、 精製 水適量を均一に分散し、 1液を加え均一に混合し、 貼付剤用膏体を得た。 これを 不織布に均一に展延し、 常法により貼付剤を得た。 実施例 1と同様にして下記の組成にて実施例 2〜8を調整した。 なお、 表に示 さなかった成分は実施例 1と同量配合した。 表 1 (単位:重量部) Polyethylene glycol 4.0 parts by weight, paraoxybenzoic acid ester 0.15 parts by weight, 1.1 menthol 0.25 parts by weight, indomethacin 0.375 parts by weight, Pepper extract (cubacinoid concentration is 20% by weight of the whole pepper extract) 0. 01 parts by weight, nonyl acid penilylamide 0.001 parts by weight, concentrated glycerin 23 parts by weight, metal metasilicate aluminate 0.08 parts by weight uniformly dispersed to form one liquid <Gelatin 1.0 parts by weight, polyvinyl alcohol 3 20 parts by weight, carmellose sodium 3.00 parts by weight, sodium polyacrylate 5.0 parts by weight, hydroxypropylcellulose 0.3 parts by weight, 70% D-sorbitol 14 parts by weight, force oil 3.0 parts by weight, Tartaric acid (1.2 parts by weight), sodium edetate (0.1 parts by weight), and an appropriate amount of purified water were uniformly dispersed, and one liquid was added and mixed uniformly to obtain a plaster for patch. This was uniformly spread on a nonwoven fabric, and a patch was obtained by an ordinary method. Examples 2 to 8 were prepared in the same manner as in Example 1 with the following compositions. Components not shown in the table were blended in the same amounts as in Example 1. Table 1 (Unit: parts by weight)
クロ夕ミトン 2. 0重量部、 パラォキシ安息香酸エステル 0. 05重量部、 1 —メントール 0. 25重量部、 インドメ夕シン 0. 375重量部、 トウガラシェ キス (カプサイシノイド濃度はトウガラシエキス全体の 20重量%) 0. 01重
量部、 ノニル酸ヮニリルアミド 0. 00 1重量部、 濃グリセリン 23重量部、 ジ ヒドロキシアルミニウムアミノアセテート 0. 08重量部を均一に分散し 1液と した。 ヒマシ油 1. 0重量部、 ポリビニルアルコール 2. 0重量部、 アクリル酸 デンプン 2. 5重量部、 ポリアクリル酸ナトリウム 6. 0重量部、 ヒドロキシプ 口ピルセルロース 0. 3重量部、 プロピレングリコール 1 5重量部、 カオリン 3. 0重量部、 酒石酸 0. 6重量部、 二酸化ケイ素 0. 5重量部、 精製水適量を均一 に分散し、 1液を加え均一に混合し、 貼付剤用膏体を得た。 これを不織布に均一 に展延し、 常法により貼付剤を得た。 実施例 10 Black mittens 2.0 parts by weight, paraoxybenzoic acid ester 0.05 parts by weight, 1-menthol 0.25 parts by weight, indomethacin 0.375 parts by weight, red pepper (capsaicinoid concentration is 20 weight parts of the whole pepper extract) %) 0.01 Parts by weight, 0.001 part by weight of nonyl acid penilylamide, 23 parts by weight of concentrated glycerin, and 0.08 parts by weight of dihydroxyaluminum aminoacetate were uniformly dispersed to form one liquid. Castor oil 1.0 part by weight, polyvinyl alcohol 2.0 parts by weight, starch acrylate 2.5 parts by weight, sodium polyacrylate 6.0 parts by weight, hydroxypyrucel cellulose 0.3 parts by weight, propylene glycol 15 Parts by weight, 3.0 parts by weight of kaolin, 0.6 parts by weight of tartaric acid, 0.5 parts by weight of silicon dioxide, and an appropriate amount of purified water are uniformly dispersed, and one liquid is added and mixed uniformly to obtain a plaster for a patch. Was. This was uniformly spread on a nonwoven fabric, and a patch was obtained by an ordinary method. Example 10
N—メチル— 2—ピロリドン 4. 5重量部、 パラォキシ安息香酸エステル 0. 05重量部、 1—メントール 0. 25重量部、 インドメタシン 0. 375重量部、 トウガラシエキス (カブサイシノィド濃度はトウガラシエキス全体の 20重量%) 0. 01重量部、 ノニル酸ヮニリルアミド 0. 00 1重量部、 濃グリセリン 20 重量部、 水酸化アルミニウム 0. 1重量部を均一に分散し 1液とした。 ポリビニ ルアルコール 3. 0重量部、 ポリアクリル酸ナトリウム 6. 0重量部、 ヒドロキ シプロピルセルロース 0. 3重量部、 70 %D—ソルビトール 25重量部、 カオ リン 3. 0重量部、 酒石酸 1. 2重量部、 ェデト酸ナトリウム 0. 12重量部、 精製水適量を均一に分散し、 1液を加え均一に混合し、 貼付剤用膏体を得た。 こ れを不織布に均一に展延し、 常法により貼付剤を得た。 実施例 1 1 4.5 parts by weight of N-methyl-2-pyrrolidone, 0.05 parts by weight of paraoxybenzoic acid ester, 0.25 parts by weight of 1-menthol, 0.375 parts by weight of indomethacin, Pepper extract (The concentration of cabsaicinoid is 20% of the total amount of pepper extract. (Weight%) 0.01 part by weight, 0.001 part by weight of nonyl acid penilylamide, 20 parts by weight of concentrated glycerin, and 0.1 part by weight of aluminum hydroxide were uniformly dispersed to form one liquid. 3.0 parts by weight of polyvinyl alcohol, 6.0 parts by weight of sodium polyacrylate, 0.3 parts by weight of hydroxypropyl cellulose, 25 parts by weight of 70% D-sorbitol, 3.0 parts by weight of kaolin, 1.2 parts of tartaric acid Parts by weight, 0.12 parts by weight of sodium edetate, and an appropriate amount of purified water were uniformly dispersed, and one part of the solution was added and uniformly mixed to obtain a plaster for a patch. This was uniformly spread on a nonwoven fabric, and a patch was obtained by an ordinary method. Example 1 1
ポリオキシエチレンソルビ夕ン脂肪族エステル 4. 0重量部、 パラォキシ安息 香酸エステル 0. 05重量部、 1—メントール 0. 25重量部、 インドメ夕シン 0. 375重量部、 トウガラシエキス (カブサイシノイド濃度はトウガラシェキ ス全体の 20重量%) 0. 01重量部、 ノニル酸ヮニリルアミド 0. 00 1重量 部、 濃グリセリン 20重量部、 合成ヒドロタルサイト 0. 1重量部、 プチルヒド ロキシトルエン 0. 1重量部を均一に分散し 1液とした。 ポリアクリル酸 3. 2 重量部、 カルメロースナトリウム 3. 0重量部、 ポリアクリル酸ナトリウム 5. 0重量部、 ヒドロキシプロピルセルロース 0. 3重量部、 70%D—ソルビトー ル 20重量部、 カオリン 3. 0重量部、 酒石酸 1. 2重量部、 精製水適量を均一 に分散し、 1液を加え均一に混合し、 貼付剤用膏体を得た。 これを不織布に均一
に展延し、 常法により貼付剤を得た c 実施例 12 4.0 parts by weight of polyoxyethylene sorbitan aliphatic ester, 0.05 parts by weight of paraoxybenzoic acid ester, 0.25 parts by weight of 1-menthol, 0.375 parts by weight of indomethacin, Capsicum extract 0.01% by weight, 0.001 part by weight of nonyl acid phenylylamide, 20 parts by weight of concentrated glycerin, 0.1 part by weight of synthetic hydrotalcite, 0.1 part by weight of butylhydroxytoluene Into one solution. 3.2 parts by weight of polyacrylic acid, 3.0 parts by weight of carmellose sodium, 5.0 parts by weight of sodium polyacrylate, 0.3 parts by weight of hydroxypropylcellulose, 20 parts by weight of 70% D-sorbitol, kaolin 3. 0 parts by weight, 1.2 parts by weight of tartaric acid, and an appropriate amount of purified water were uniformly dispersed, and one part of the solution was added and uniformly mixed to obtain a plaster for a patch. This is uniformly applied to the nonwoven fabric C Example was spread was obtained by a conventional method patch 12
ポリオキシエチレンソルビ夕ン脂肪族エステル 0. 3重量部、 ポリエチレング リコール 4. 0重量部、 パラォキシ安息香酸エステル 0. 05重量部、 1ーメン トール 0. 25重量部、 インドメ夕シン 0. 375重量部、 トウガラシエキス (カブサイシノイド濃度はトウガラシエキス全体の 20重量%) 0. 0 1重量部、 ノニル酸ヮニリルアミド 0. 00 1重量部、 プロピレングリコ一ル 20重量部、 乾燥水酸化アルミニウムゲル 0. 08重量部を均一に分散し 1液とした。 ポリア クリル酸 3. 0重量部、 カルメロ一スナトリウム 3. 5重量部、 ポリアクリル酸 ナトリウム 5. 0重量部、 ヒドロキシプロピルセルロース 0. 3重量部、 70% D_ソルビトール 1 5重量部、 カオリン 3. 0重量部、 酒石酸 1. 2重量部、 ェ デト酸ナトリウム 0. 1重量部、 精製水適量を均一に分散し、 1液を加え均一に 混合し、 貼付剤用膏体を得た。 これを不織布に均一に展延し、 常法により貼付剤 を得た。 試験例 1 0.3 parts by weight of polyoxyethylene sorbitan aliphatic ester, 4.0 parts by weight of polyethylene glycol, 0.05 part by weight of paraoxybenzoate, 0.25 parts by weight of 1-menthol, 0.375 parts by weight of indomethacin Parts, Capsicum extract (concentration of capsaicinoid is 20% by weight of the total capsicum extract) 0.0 1 part by weight, nonyl acid penilylamide 0.001 part by weight, propylene glycol 20 parts by weight, dry aluminum hydroxide gel 0.08 parts by weight Parts were uniformly dispersed to form one liquid. 3.0 parts by weight of polyacrylic acid, 3.5 parts by weight of sodium carmellose, 5.0 parts by weight of sodium polyacrylate, 0.3 parts by weight of hydroxypropylcellulose, 15 parts by weight of 70% D_sorbitol, 3 parts by weight of kaolin 0.0 part by weight, 1.2 parts by weight of tartaric acid, 0.1 part by weight of sodium edetate and an appropriate amount of purified water were uniformly dispersed, and one liquid was added and mixed uniformly to obtain a plaster for patch. This was uniformly spread on a nonwoven fabric, and a patch was obtained by an ordinary method. Test example 1
実施例 1〜 4及び比較例の貼付剤を 3名の被験者の右肩及び左肩に貼付した。 6時間貼付した際のそれぞれの貼付剤の温感、 気持ちよさ、 効き目感、 皮膚刺激 について以下のように評価を行い、 その平均値を表 2に示した。 The patches of Examples 1 to 4 and Comparative Example were applied to the right and left shoulders of three subjects. Each patch was evaluated for warmth, pleasure, effectiveness, and skin irritation when applied for 6 hours as follows, and the average value is shown in Table 2.
とてもよい 7点 : よい 6点 : ややよい 5点 Very good 7 points: Good 6 points: Good 5 points
ふつう 4点 : やや悪い 4点 : 悪い 2点 Normal 4 points: Somewhat bad 4 points: Bad 2 points
とても悪い 1点 表 2 Very bad 1 point Table 2
①温感 ②気持ちよさ ③効き目感 ④皮膚刺激 実施例 1 6.7 6.3 6.7 な し ① Warm feeling ② Comfortable ③ Effectiveness ④ Skin irritation Example 1 6.7 6.3 6.7 None
屑 実施例 2 5.7 6.0 5.7 な し Scrap Example 2 5.7 6.0 5.7 None
用 実施例 3 5.7 5.7 5.3 な し Example 3 5.7 5.7 5.3 None
実施例 4 6.3 6.3 6.3 な し
試験例 2 Example 4 6.3 6.3 6.3 None Test example 2
実施例 5〜 8の貼付剤を 3名の被験者の腰部に貼付した。 6時間貼付した際の それぞれの貼付剤の温感、 気持ちよさ、 効き目感、 皮膚刺激について試験例 1と 同様に評価を行い、 その平均値を表 3に示した。 表 3 The patches of Examples 5 to 8 were applied to the lumbar regions of three subjects. Each patch was evaluated for warmth, pleasure, effectiveness, and skin irritation when applied for 6 hours in the same manner as in Test Example 1. The average value is shown in Table 3. Table 3
①温感 ②気持ちよさ ③効き目感 ④皮虜刺激 実施例 5 5. 3 5. 3 5. 7 な し ① Warm feeling ② Comfortable ③ Effectiveness 刺激 Stimulation of skin capture Example 5 5. 3 5. 3 5. 7 None
腰 実施例 6 6. 3 6. 3 6. 3 な し Waist Example 6 6. 3 6. 3 6. 3 None
用 5. 7 5. 3 5. 7 な し 5. 7 5. 3 5. 7 None
実施例 8 6. 0 6. 3 6. 7 な し
Example 8 6. 0 6. 3 6. 7 None
Claims
1. 水溶性高分子基剤を含有する貼付剤において、 カブサイシノイド及びノニル 酸ヮニリルアミドを配合し、 かつ、 基剤 1 00 gに対するカブサイシノィドの配 合量を [X] (g) 、 ノニル酸ヮニリルアミドの配合量を [Y] (g) とした場合、 [X]が 0. 0002〜 0. 005であり、 [ Y] が 0. 0005〜 0. 007で あることを特徴とする貼付剤。 1. In a patch containing a water-soluble polymer base, blend cabsaicinoid and nonyl acid penilylamide, and mix the amount of cabsaicinoid with 100 g of base [X] (g) and nonyl acid penilylamide. A patch characterized in that when the amount is [Y] (g), [X] is 0.0002 to 0.005, and [Y] is 0.0005 to 0.007.
2. 水溶性高分子基剤を含有する貼付剤において、 カブサイシノイド及びノニル 酸ヮニリルアミドを配合し、 かつ、 基剤 100 gに対するカブサイシノイドの配 合量を [X] (g) 、 ノニル酸ヮニリルアミドの配合量を [Y] (g) とした場合、 [Y]が 0. 0005〜0. 003であり、 [X] + 0. 6 [丫]が0. 0020〜0 0028であることを特徴とする貼付剤。 2. In a patch containing a water-soluble polymer base, cabsaicinoid and nonyl acid penilylamide are mixed, and the amount of cabsaicinoid per 100 g of the base is [X] (g), and the amount of nonyl acid penilylamide is mixed. Is [Y] (g), [Y] is 0.0005 to 0.003, and [X] +0.6 [丫] is 0.0002 to 00028. Agent.
3. 水溶性高分子基剤を含有する貼付剤において、 カブサイシノイド及びノニル 酸ヮニリルアミドを配合し、 かつ、 基剤 1 00 gに対するカブサイシノイドの配 合量を [X] (g) 、 ノニル酸ヮニリルアミドの配合量を [Y] (g) とした場合、 [Y]が 0. 0005〜0. 007であり、 かつ、 [X] + 0. 6 X[Y]が 0. 004 6〜0. 0052であることを特徴とする貼付剤。 3. In a patch containing a water-soluble polymer base, blend cabsaicinoid and nonyl acid penilylamide, and adjust the amount of cabsaicinoid to 100 g of the base with [X] (g) and nonyl acid penilylamide. When the quantity is [Y] (g), [Y] is 0.0005 to 0.007, and [X] +0.6 X [Y] is 0.0004 6 to 0.0005. A patch characterized in that:
4. カプサイシノィドがトウガラシ由来のものである請求の範囲の第 1項〜第 3 項のいずれかに記載の貼付剤。 4. The patch according to any one of claims 1 to 3, wherein the capsaicinoid is derived from a pepper.
5. 水溶性高分子基剤が基剤全体に対し 35〜80重量%の水を含有する請求の 範囲第 1項〜第 4項のいずれかに記載の貼付剤。 5. The patch according to any one of claims 1 to 4, wherein the water-soluble polymer base contains 35 to 80% by weight of water based on the whole base.
6. さらにインドメ夕シンを配合した請求の範囲第 1項〜第 5項のいずれかに記 載の貼付剤。
6. The patch according to any one of claims 1 to 5, further comprising indomethacin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63196/00A AU6319600A (en) | 1999-08-05 | 2000-08-04 | Patch |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22261699 | 1999-08-05 | ||
JP11/222616 | 1999-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001010435A1 true WO2001010435A1 (en) | 2001-02-15 |
Family
ID=16785257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/005269 WO2001010435A1 (en) | 1999-08-05 | 2000-08-04 | Patch |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6319600A (en) |
WO (1) | WO2001010435A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047820A1 (en) | 2002-11-27 | 2004-06-10 | Hisamitsu Pharmaceutical Co., Inc. | Warm poultice |
WO2007114380A1 (en) * | 2006-03-31 | 2007-10-11 | Kobayashi Pharmaceutical Co., Ltd. | Agent for external application to the skin |
TWI734953B (en) | 2018-01-24 | 2021-08-01 | 日商久光製藥股份有限公司 | Patch |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5391114A (en) * | 1977-01-21 | 1978-08-10 | Riido Kemikaru Kk | Pappu medicine stimulated by narming |
JPH05105628A (en) * | 1991-10-14 | 1993-04-27 | Lion Corp | Antiinflammatory analgesic for external use |
JPH10298066A (en) * | 1997-04-24 | 1998-11-10 | Taisho Pharmaceut Co Ltd | Plaster having warm feeling |
-
2000
- 2000-08-04 WO PCT/JP2000/005269 patent/WO2001010435A1/en active Application Filing
- 2000-08-04 AU AU63196/00A patent/AU6319600A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5391114A (en) * | 1977-01-21 | 1978-08-10 | Riido Kemikaru Kk | Pappu medicine stimulated by narming |
JPH05105628A (en) * | 1991-10-14 | 1993-04-27 | Lion Corp | Antiinflammatory analgesic for external use |
JPH10298066A (en) * | 1997-04-24 | 1998-11-10 | Taisho Pharmaceut Co Ltd | Plaster having warm feeling |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047820A1 (en) | 2002-11-27 | 2004-06-10 | Hisamitsu Pharmaceutical Co., Inc. | Warm poultice |
CN100372526C (en) * | 2002-11-27 | 2008-03-05 | 久光制药株式会社 | Warm poultice |
WO2007114380A1 (en) * | 2006-03-31 | 2007-10-11 | Kobayashi Pharmaceutical Co., Ltd. | Agent for external application to the skin |
JP2007269693A (en) * | 2006-03-31 | 2007-10-18 | Kobayashi Pharmaceut Co Ltd | Skin care preparation |
TWI734953B (en) | 2018-01-24 | 2021-08-01 | 日商久光製藥股份有限公司 | Patch |
Also Published As
Publication number | Publication date |
---|---|
AU6319600A (en) | 2001-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2002100384A1 (en) | Sheet patch | |
JP2004174202A (en) | Plaster | |
JP3553174B2 (en) | Sheet pack | |
JP4596751B2 (en) | Anti-inflammatory analgesic patch | |
US20060079640A1 (en) | Adhesive composition for dermal patch and production process thereof | |
JP2002020274A (en) | Non-steroidal anti-inflammatory analgesic transdermal patch agent for outer application and transdermal patch for outer application | |
JP4677063B2 (en) | Dutch mustard extract combination external preparation | |
JPWO2003002075A1 (en) | Sheet pack | |
JP2011074032A (en) | Pharmaceutical composition for external use | |
WO2001087244A1 (en) | Sheet-type packs | |
JP2002029993A (en) | Plaster | |
JPH05105628A (en) | Antiinflammatory analgesic for external use | |
JPH0662401B2 (en) | Ketoprofen-containing patch | |
JP4575632B2 (en) | Drugs for migraine relief | |
JPH08243377A (en) | Alcohol-containing gel body | |
WO2001010435A1 (en) | Patch | |
JP2009023922A (en) | Liniment targeting amelioration of stiff neck, stiff shoulder due to age, various joint pains or the like | |
JP3197222B2 (en) | Powdery nasal composition | |
JPH07228537A (en) | Water-based thermesthesic application agent | |
CN109381466A (en) | Promote the therapeutic agent of diabetic wound healing | |
JP4038580B2 (en) | Patch | |
JPS59118719A (en) | Preparation of plaster gel for poultice | |
JP4171305B2 (en) | Packing agent using water-soluble nonwoven fabric | |
JP2004168764A (en) | Adhesive composition for patch preparation and method for producing the same | |
CN108721253A (en) | A kind of warming gel ointment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase |